Visual abstract | PSOARING 3: 52-week safety and efficacy of tapinarof cream

The Psoriasis and Psoriatic Arthritis Hub is happy to present a visual abstract summarizing key findings from the phase III PSOARING 3 trial evaluating the long-term efficacy and safety of tapinarof 1% cream in patients with plaque psoriasis. Included patients had received 12 weeks of prior treatment with tapinarof or vehicle cream PSOARING 1 or 2 trials.

Overall, patients were enrolled for a total of 52 weeks (12 weeks in PSOARING 1 or 2, plus 40 weeks in PSOARING 3).¹ In PSOARING 1 and 2, patients were randomly assigned 2:1 to tapinarof cream and vehicle.² In PSOARING 3, patients received tapinarof until a PGA score of 0 was achieved and were monitored for remittive effect, with a total of 40.9% of patients achieved a PGA of 0 at least once during the trial.¹

Results from the PSOARING 3 trial demonstrate the consistent safety profile and sustained efficacy of tapinarof cream at 52 weeks.